Press release from Companies
Publicerat: 2025-06-03 17:45:00
Copenhagen, Denmark, 3 June 2025 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces that the exercise price for the warrants of series TO3 ("TO3"), which were issued in connection with the directed issue and rights issue of units the Company executed earlier during 2024, has been set. The exercise price for TO3 has been set to DKK 15.55 per share, which is the minimum price and the exercise period commences on 4 June 2025.
The minimum price of DKK 15.55 is far above the current market price, however, Curasight is obliged under the company's articles of association to complete the execution of the T03 warrants on the stated terms, which were determined in 2024. The board of directors do not expect that any of the TO3 warrants will be exercised.
In September 2024, Curasight carried out both a rights issue and directed issue of units. Through the rights issue and directed issue 1,841,907 warrants of series TO3 were issued. Each TO3 entitles the holder to subscribe for one (1) new share in Curasight during the exercise period, which runs from and including 4 June 2025 until and including 18 June 2025. The exercise price for TO3 has been set at DKK 15.55 per share. In the event of full utilization of warrants of series TO3, approximately DKK 28.6 million will be added to the Company before issue costs.
Upon full utilization of TO3, the number of shares in Curasight will increase by 1,841,907 shares to a total of 47,705,917 shares and the share capital will increase by DKK 92,095.35 to DKK 2,385,295.85. The dilution at full utilization amounts to approximately 3.9 percent of the capital and votes.
Terms and instructions for warrants of series TO3 will be available on the Company's website (www.curasight.com).
Important dates
Advisors
Sedermera Corporate Finance AB is the Company's financial advisor in connection with the capitalization. DLA Piper is the Company's legal advisor and Danske Bank is the settlement agent.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
For more information regarding the warrants, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.
